Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	43.48	24.23	34.95	144.51	47.08
Short-Term Investments	83.24	128.23	151.66	-	-
Cash & Short-Term Investments	126.72	152.46	186.61	144.51	47.08
Cash Growth	-16.88%	-18.30%	29.13%	206.98%	86.05%
Prepaid Expenses	6.03	1.42	8.18	2.59	3.13
Total Current Assets	132.75	153.88	194.79	147.11	50.2
Property, Plant & Equipment	7.08	2.67	4.53	6.33	1.13
Other Long-Term Assets	0.57	0.32	0.32	0.32	0.58
Total Assets	140.4	156.88	199.65	153.76	51.91
Accounts Payable	2.25	4.09	3.38	0.87	1.06
Accrued Expenses	6.29	2.51	11.69	8.78	1.57
Current Portion of Long-Term Debt	-	-	-	-	7.47
Current Portion of Leases	0.34	1.2	1.1	0.99	-
Total Current Liabilities	8.87	7.8	16.17	10.63	10.1
Long-Term Debt	-	-	-	-	1.87
Long-Term Leases	6.3	0.54	1.84	3.05	-
Total Liabilities	15.17	8.34	18.01	13.68	11.97
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	489.69	463.8	454.74	373.66	191.35
Retained Earnings	-364.68	-315.31	-272.81	-233.59	-151.41
Comprehensive Income & Other	0.21	0.04	-0.3	-	-
Total Common Equity	125.23	148.54	181.64	140.08	39.95
Shareholders' Equity	125.23	148.54	181.64	140.08	39.95
Total Liabilities & Equity	140.4	156.88	199.65	153.76	51.91
Total Debt	6.63	1.73	2.94	4.04	9.33
Net Cash (Debt)	120.09	150.73	183.67	140.48	37.74
Net Cash Growth	-20.33%	-17.94%	30.75%	272.20%	279.70%
Net Cash Per Share	0.87	1.19	1.75	2.23	1.23
Filing Date Shares Outstanding	138.28	137.59	126.31	100.83	51.22
Total Common Shares Outstanding	137.82	127.67	126.3	100.83	51.22
Working Capital	123.88	146.08	178.62	136.47	40.1
Book Value Per Share	0.91	1.16	1.44	1.39	0.78
Tangible Book Value	125.23	148.54	181.64	140.08	39.95
Tangible Book Value Per Share	0.91	1.16	1.44	1.39	0.78
Machinery	4.74	5.19	5.16	5.37	5.99
Leasehold Improvements	1.61	1.61	1.61	1.53	0.9

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q